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Background: Pain is a common occurrence and persistent symptom, which has an adverse
impact on individual well-being and quality of life among people living with HIV (PLHIV).
Alteration in the activity of the Hypothalamic-Pituitary-Adrenal (HPA) axis resulting in
abnormal glucocorticoid levels had been proposed to play important roles in those
associations.
Purpose: This study aimed to investigate whether pain severity was associated with hair
glucocorticoid levels, a novel method of measuring long-term glucocorticoid exposure,
among a large cohort of Chinese PLHIV.
Methods: A measure of pain severity and hair samples were collected from 431 adults
PLHIV in Guangxi, China. Glucocorticoid (cortisol and cortisone) in hair were quantified by
liquid chromatography-tandem mass spectrometry. The general linear model was used to test
the associations of pain severity with hair glucocorticoid levels after adjusting for potential
confounding factors.
Results: Of the 431 PLHIV, 273 reported none pain, 87 reported mild pain, and 71 reported
moderate-severe pain. Hair cortisone, but not hair cortisol, was found to differ significantly
among the three pain severity groups (F=3.90, p=0.021). PLHIV reported moderate-severe
pain had higher hair cortisone than those reported mild (p=0.070) or none pain (p=0.014),
with no differences between the latter two pain severity groups.
Conclusion: Greater pain severity is associated with higher hair cortisone levels among
Chinese PLHIV. In order to reduce the long-term glucocorticoid levels, interventions mana
ging pain should be considered for PLHIV with moderate-severe pain.
Keywords: pain, hair cortisol, hair cortisone, HIV

Introduction
Pain is one of the most commonly reported and persistent symptoms among people
living with HIV (PLHIV), affecting 54% to 83% PLHIV, as indicated by
a systematic review.1 The etiology of pain in PLHIV is varied and includes the
direct effects of HIV on nervous systems, resultant opportunistic infections, side
effects of combination antiretroviral therapy (cART), or other conditions unrelated
to HIV.2 Regardless of etiology, pain in PLHIV is a significant source of function
loss3 and decreased quality of life,4 and has been associated with elevated levels of
psychological distress, including anxiety and depression,5–8 as well as higher
adverse behaviors, including substance use9,10 and suboptimal ART
adherence.11–13 While the increased attention has been paid to the relationship
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between pain and these adverse outcomes in PLHIV, lim
ited data are available concerning the biological mechan
isms underlying these associations in PLHIV.
The hypothalamic-pituitary-adrenal (HPA) axis is one
of the main stress-sensitive systems regulating the body’s
adaptation to stress by secretion of the glucocorticoid
hormone.14,15 There is substantial evidence for a relation
of hyper- or hypo-secretion of glucocorticoid with adverse
health outcomes.16 Pain has been conceptualized as one
type of stress that adds strain on the organism.17,18
Therefore, glucocorticoid is considered to play a crucial
role in mediating the link between pain and the develop
ment of adverse health outcomes. While previous studies
have investigated the relationship between pain and glu
cocorticoid levels in patients with chronic pain,19–24 criti
cal gaps in the relationship between pain and
glucocorticoid levels in PLHIV remain unaddressed.
As well known, cortisol is an active glucocorticoid, and
cortisone is an inactive glucocorticoid originating from the
local conversion of cortisol by the 11β hydroxysteroid
dehydrogenase (11β-HSD) type 2 enzyme, and 11β-HSD
type1 enzyme is responsible for the reversible conversion
of cortisone to cortisol.25 Therefore, the interaction
between cortisol and cortisone regulates stress-induced
psychological and physiological responses together.26,27
In addition, cortisone levels are higher than those of corti
sol levels in biomatrix (e.g., saliva and urine).25,28
Moreover, cortisone levels could more closely approxi
mate unbound, biologically active cortisol levels than
total cortisol levels.25 Therefore, the assessment of corti
sone in parallel with cortisol could provide a more sys
tematic evaluation of the glucocorticoid exposure.29
The conventional methods for cortisol and cortisone
assessment in serum, saliva, or urine are susceptible to
reflect mainly short-term cortisol and cortisone levels and
affect by the circadian rhythm and other daily
fluctuations.30 Recently, another method measures cortisol
and cortisone levels in scalp hair, which circumvents many
limitations of the previous methods and enables retrospec
tive assessment of cortisol and cortisone levels in the past
weeks to months, depending on the length of the collected
sample.31 Comparing between hair cortisol and cortisone
levels and cortisol and cortisone levels in repeated saliva
sampling,29,32–34 testing the test-retest reliability of hair
cortisol and cortisone levels across a period of several
months to a year,28,35 and employing hair cortisol and
cortisone levels in stress or chronic disease research,36–40
all suggest that hair cortisol and cortisone levels are novel
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retrospective indicators of long-term glucocorticoid expo
sure. To our knowledge, only two studies employed hair
cortisol levels in HIV-related research.41,42 Limited data
are available on employing hair cortisone levels in HIVrelated research, and no study examined the association
between pain severity and glucocorticoid levels in PLHIV
by employing hair cortisol and cortisone levels.
Accordingly, we assessed pain severity and hair corti
sol and cortisone levels in a large cohort of PLHIV in
Guangxi, China, and aimed to examine whether pain
severity was associated with hair cortisol and cortisone
levels among Chinese PLHIV.

Methods
Participants
The participants of this study were recruited from an HIV
disclosure study aiming to investigate the mechanism of
the effects of HIV disclosure on clinical outcomes in
Guangxi, China.43–45 With the assistance and collaboration
of the Guangxi Center for Disease Prevention and Control
(CDC), ten clinic sites with the largest number of HIV
patients under care from 17 cities and 75 counties in
Guangxi were selected as study sites.
The inclusion criteria were: (1) at least 18 years of age;
(2) a confirmed diagnosis of HIV; (3) willing to provide
hair samples; and (4) willing to consent the retrieval of
their relevant clinical outcome data (eg, CD4+ T cell
count) from their medical charts. The exclusion criteria
were: (1) linguistic, mental or physical inability to respond
to assessment questions; (2) opportunistic infections, coin
fection, comorbidities, endocrine diseases, or reported any
other diseases; (3) currently take hormonal drugs (eg,
prednisolone); (4) known history of drug use; (5) chemical
hair treated (eg, dyed, permed, or bleached) or scalp hair
in the posterior vertex was less than 1 cm.
Medical staff or HIV case managers at the study sites
referred potential participants to the research term members.
Research team members screened PLHIV for eligibility,
discussed the benefits and risks of the study, and invited
them to participate. Research team members were local
CDC staff or health care workers in the HIV clinics who
had received intensive training on research ethics and inter
view skills with PLHIV before the field data and hair speci
men collection. Finally, a total of 446 PLHIV participated in
this study. This study followed the Declaration of Helsinki
and was approved by the Institutional Review Boards of the
University of South Carolina in the United States and the
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Guangxi CDC in China. The written informed consent also
has been obtained from the participants.

Hair and Data Collection
Hair samples were cut from the posterior vertex region
as close as possible to the scalp following a standard
protocol46,47 in private rooms of local CDC or HIV
clinics. The hair strands were cut with iron scissors
that had been wiped with an alcohol pad. The hair
thatch then was completely enclosed by a piece of foil,
and a small label indicating the study ID number was
placed over the distal end of the hair thatch. Then, the
interviewer-administered questionnaire was used for
data collection. After the hair sample collection, the
interviewer-administered questionnaire was used for the
collection of sociodemographic, lifestyle, and HIVrelated information. Each participant received a gift
with a value equal to the US $5.00 (≈ 35 Chinese
Yuan) after finished the survey.

Pain Measure
To assess pain severity, we asked participants the fol
lowing single-item question: “how much pain have you
generally had during the past month”.48,49 Response
options were on a 6-point scale ranging from “none”
to “very severe.” Given that pain data are generally
skewed, we divided our sample into three groups: those
who reported none pain, those who reported mild pain,
and those who reported moderate-severe pain.

Hair Cortisol and Cortisone
The proximal 1 cm of hair segments (approximately
reflect the last month of accumulative cortisol and cor
tisone levels) was cut finely with scissors, and 20 mg
were processed and analyzed using liquid chromatogra
phy-tandem mass spectrometry (LC/MS/MS) followed
the protocol described by Gao and colleagues.50 The
method showed good linearity (R2 > 0.99) in the range
of 0.25–1250 pg/mg for both cortisol and cortisone, the
limit of detection (LOD) for both cortisol and cortisone
at 0.1 pg/mg, and the limit of quantitation (LOQ) for
both cortisol and cortisone at 0.3 pg/mg. Intra-day and
inter-day percentages coefficient of variation (CV) were
less than 7% at standard concentrations of 1.25, 25, and
250 pg/mg, and recovery ranged between 95% and
107% for both cortisol and cortisone.
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Sociodemographic and Clinical
Characteristics
Participants provided information on their sociodemo
graphic that might have a potential influence on hair corti
sol and cortisone levels,30,51,52 including age (years),
gender (male vs female), ethnicity (Han vs non-Han),
marital status (married vs other), education level (> 9
years vs ≤ 9 years), employment status (employed vs
unemployed), monthly household income level (≥ 3000
Yuan vs < 3000 Yuan).
Clinical characteristics were abstracted from the parti
cipants’ medical charts, including the date of HIV diag
nosis, cART status, and CD4+ T cell count. Years of HIV
diagnosis referred to the period from the initial date of
confirmed HIV diagnosis to the time of the survey. CD4+
T cell count was dichotomized as >500 cells/mm3 vs ≤500
cells/mm3 because the low limit of normal CD4+ T cell
count is 500 cells/mm3 in adults. The cART status was
category into untreated and cART treated.

Data Analysis
Fifteen participants were excluded from the final analysis
because of the insufficient weight of hair samples (less
than 20mg) for assaying cortisol and cortisone (n=13) or
unavailable data of pain measure (n=2). This left 431
participants for analysis.
Hair cortisol and cortisone levels were not normally
distributed as indicated by the Kolmogorov–Smirnov test
and were thus Winsorized (5th/95th percentile),53 and
Box-Cox transformed54 for effectively reduced the skew
ness statistic. Univariate linear regression analysis was
used to explore the associations of hair cortisol or hair
cortisone with sociodemographic and clinical characteris
tics. The general linear model was used to examine differ
ences in transformed glucocorticoid levels among the three
pain studied groups. Findings of significant main effects
were followed up by post hoc comparisons using LSD.
Multivariate analysis of covariance was adjusted for socio
demographic and clinical characteristics. All data analyses
were performed using SPSS 26.0 (SPSS Inc, Chicago, IL).

Results
Of the 431participants with a mean (SD) age of 41 (8) years
(Table 1), 68% were male, 61.9% were Han ethnicity,
78.9% were married, 77.7% were employed, 91.2% were
receiving cART. Most of the sample had low levels of
education and income, with 89.6% reporting not complete
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Table 1 Characteristics of the 431 Participants
Characteristics

n(%), M (SD) or Median (IQR)

Age

41.33 (8.38)

Table 2 Univariate Regressions of Hair Cortisol and Cortisone
Levels with Sociodemographic and Clinical Characteristics
Hair Cortisol
β

p

β

p

Age

0.111

0.022

0.066

0.173

Gender

0.084

0.082

0.214

< 0.001

Ethnicity

0.096

0.045

0.022

0.642

Marital status

0.082

0.088

0.001

0.981

Education level

−0.103

0.033

−0.013

0.792

Employment status

−0.018

0.704

−.0.037

0.444

Monthly income level

−0.191

< 0.001

−0.011

0.825

Years since HIV diagnosis

−0.026

0.597

0.015

0.758

cART status

−0.026

0.584

−0.007

0.889

CD4+ T cell count

0.016

0.741

0.075

0.118

Gender
Male
Female

293 (68.0%)
138 (32.0%)

Ethnicity
Han

267 (61.9%)

No Han

164 (38.1%)

Marital status
Married
Other
Education
≤ 9 years
> 9 years

340 (78.9%)
91(21.1%)

386 (89.6%)

Hair Cortisone

45 (10.4%)

Employment
Employed

335 (77.7%)

Unemployed

96 (22.3%)

Abbreviations: β, standardized coefficient; cART, combination antiretroviral
therapy.

Income level
≥3000 Yuan per month
< 3000 Yuan per month
Years since HIV diagnosis

103(23.9%)
328 (76.1%)
1.50 (0.92–2.25)

cART status
Yes

393 (91.2%)

No

38 (8.8%)

CD4 count, cells/mm3

359 (204–532)

Pain severity
None

273 (63.3%)

Very mild
Mild

37 (8.6%)
50 (11.6%)

Moderate

63 (14.6%)

Severe
Very severe

5 (1.2%)
3 (0.7%)

Hair cortisol, pg/mg

7.60 (4.98–11.74)

Hair cortisone, pg/mg

44.02 (31.12–67.15)

Abbreviations: M, mean; SD, standard deviation; IQR, interquartile range; cART,
combination antiretroviral therapy.

junior high school and 76.1% reporting a monthly house
hold income of less than 3000 Chinese Yuan (or approxi
mately US$460 during the time of the survey). The median
CD4+ T cell count was 359 cells/mm3, and the median
duration of HIV diagnosis was 1.50 years. Among the 431
PLHIV, 273 (63.3%) reported none pain, 87 (20.2%)
reported very mild or maid pain, and 71 (16.5%) reported
moderate, severe, or very severe pain. The median cortisol
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and cortisone levels were 7.60 pg/mg and 44.02 pg/mg,
respectively. Hair cortisol and hair cortisone levels were
positively correlated (r = 0.26, p < 0.001).
Table 2 shows the univariate regression of hair cor
tisol and cortisone levels with sociodemographic and
clinical characteristics, respectively. Age, no-Han ethni
city, and be married were positively associated with hair
cortisol levels. Female sex was positively associated
with both hair cortisol and cortisone levels. Education
levels and income levels were negatively associated
with hair cortisol levels. Clinical characteristics were
not associated with either hair cortisol levels or hair
cortisone levels.
The median hair cortisol levels were 7.09 pg/mg,
8.07 pg/mg, and 7.93 pg/mg for the none, maid, and
moderate-severe pain groups, respectively (see Figure
1). No significant difference was found in hair cortisol
levels among the three pain groups (F=0.14, p=0.868).
The median hair cortisone levels were 41.78 pg/mg,
47.71 pg/mg, and 51.62 pg/mg for the none, maid, and
moderate-severe pain groups, respectively (see Figure
2). A significant difference was detected in hair corti
sone levels (F=3.90, p=0.021). Post hoc analyses for
transformed data revealed that PLHIV with moderatesevere pain had higher hair cortisone levels than those
with none pain (p=0.014) and had marginally higher
cortisone levels than those with maid pain (p=0.070),
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Figure 1 Hair cortisol levels (pg/mg) in none, mild, and moderate-severe pain
groups. Horizontal lines represent the group median.

Figure 2 Hair cortisone levels (pg/mg) in none, mild, and moderate-severe pain
groups. Horizontal lines represent the group median.

with no difference between the latter two groups
(p>0.10). Adjusting for the covariates on these measures
also did not alter the result for hair cortisol
levels (F=0.02, p=0.983) or hair cortisone levels
(F=4.03, p=0.018).

Discussion
The present study investigated whether pain severity was
associated with hair glucocorticoid levels, a novel method
of measuring long-term glucocorticoid exposure, among
a large cohort of Chinese PLHIV. We found nonsignificant
difference in hair cortisol levels among the three pain
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groups. However, PLHIV with moderate-severe pain had
higher hair cortisone levels than those with mild pain or
none pain, with no difference between PLHIV with mild
pain and none pain.
To the best of our knowledge, only two previous stu
dies investigated the relationship between pain and hair
cortisol levels in patients with chronic pain, and no study
has directly examined the relationship between pian and
hair cortisone levels. Our finding regarding the lack of
association of pain severity with hair cortisol levels in
PLHIV is inconsistent with the two previous studies that
reported higher hair cortisol levels in patients with chronic
pain than controls.21,24 However, we found that PLHIV
with moderate-severe pain had higher hair cortisone levels
than those with none pain or mild pain. There are two
potential explanations for why significant associations
were demonstrated for hair cortisone levels, but not hair
cortisol levels in our study. Firstly, hair cortisone levels
could indicate more systematic glucocorticoid levels than
hair cortisol levels. In line with the previous
evidence,39,55,56 our data also found that hair cortisone
levels were higher than hair cortisol levels (Table 1) and
positively correlated. Previous studies also found that sali
vary cortisone levels demonstrated a stronger correlation
with free serum cortisol levels than total serum cortisol
levels and salivary cortisol levels25 and salivary cortisone
levels showed a considerable correlation with hair
cortisone levels.29 Therefore, hair cortisone levels have
been employed as an additional measure of systematic
glucocorticoid levels.26,27 Secondly, hair cortisone levels
also appear- to hold certain benefits to hair cortisol levels.
For instance, both our study (see Table 2) and previous
studies found hair cortisol levels were influenced by addi
tional factors.51,52 Other studies have also found stronger
associations between hair cortisone levels than hair corti
sol levels and variables studied, including Parkinson’s
disease,40 cardiometabolic variables,37,56 and stressrelated variables.36,40 One study found diagnostic accuracy
for Cushing’s syndrome was significantly better for hair
cortisone levels than hair cortisol levels.57 Therefore,
along with previous studies, our study also provides impli
cations for future research to consider both hair cortisol
levels and hair cortisone levels, rather than hair cortisol
levels alone to represent long-term glucocorticoid levels.
Regardless of the relatively little is known about corti
sone’s physiological significance, our findings regarding
the association between pain severity and hair cortisone
levels indicated that health providers in caring for PLHIV
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should consider interventions (eg, mindfulness) to reduce
the long-term glucocorticoid levels and to manage
pain.58,59
We found that clinical characteristics were not asso
ciated with hair cortisol or cortisone levels. Two recent
studies also reported no association between hair cortisol
levels and CD4+ T cell counts42 or cART status.41 In
addition, our results contribute to HIV research by explor
ing the association of several other sociodemographic
variables with hair glucocorticoid levels in a large cohort
study and other fields by confirming the association of
those variables with hair glucocorticoid levels previously
observed in a different population.51,52
Several study limitations need to be acknowledged. First,
the current study was based on cross-sectional data, which
prevents making causal inferences. Future research should
benefit from using longitudinal designs to investigate
whether the change in glucocorticoid levels is consistent in
PLHIV who experienced pain and whether the possible cause
of pain in PLHIV is abnormalities of the glucocorticoid
levels. Second, we only employed single-item questions to
assess pain severity. Several other essential pain components
were not evaluated in our study, including the pain site,
chronicity and frequency of pain, pain coping, and pain
medical history. Future research should benefit from employ
ing multiple validity pain scales (eg, brief pain inventory and
verbal numerical rating scale) that can include those compo
nents of pain. Third, because all participants are from
Guangxi, China, these findings may not be generalizable to
other PLHIV settings. Fourth, while data were not available
in the current study on some other potential factors (eg,
physical exercise) that might influence hair glucocorticoid
levels,30,60 those factors should be considered in future
research.

Conclusion
In summary, this study is the first to report that greater
pain severity is associated with higher hair cortisol levels
among Chinese PLHIV. In order to reduce the long-term
glucocorticoid levels, interventions managing pain should
be considered for PLHIV with moderate-severe pain.
Future work will focus on the longitudinal relationship
between these variables and further explore hair corti
sone’s utility as a neuroendocrine biomarker in PLHIV.

Acknowledgments
The authors thank the study participants and data collec
tors for their collaboration during the data collection.

650

Powered by TCPDF (www.tcpdf.org)

submit your manuscript | www.dovepress.com

DovePress

Funding
This study was supported by the National Institutes of
Health (NIH) Research Grant [Grant numbers
R01HD074221, R21AI122919].

Disclosure
All authors declare that they have no conflict of interest.

References
1. Parker R, Stein DJ, Jelsma J. Pain in people living with HIV/AIDS:
a systematic review. J Int AIDS Soc. 2014;17(1):18719. doi:10.7448/
IAS.17.1.18719
2. Hewitt DJ, McDonald M, Portenoy RK, Rosenfeld B, Passik S,
Breitbart W. Pain syndromes and etiologies in ambulatory AIDS
patients. Pain. 1997;70(2–3):117–123. doi:10.1016/S0304-3959(96)
03281-2
3. Merlin JS, Westfall AO, Chamot E, et al. Pain is independently
associated with impaired physical function in HIV-infected patients.
Pain Med. 2013;14(12):1985–1993. doi:10.1111/pme.12255
4. da Silva JG, da Rocha Morgan DA, Melo FCM, et al. Level of pain
and quality of life of people living with HIV/AIDS pain and quality
of life in HIV/AIDS. AIDS Care. 2017;29(8):1041–1048.
5. Tsao JC, Dobalian A, Naliboff BD. Panic disorder and pain in
a national sample of persons living with HIV. Pain. 2004;109
(1–2):172–180.
6. Evans S, Ferrando S, Sewell M, Goggin K, Fishman B, Rabkin J.
Pain and Depression in HIV Illness. Psychosomatics. 1998;39
(6):528–535.
7. Uebelacker LA, Weisberg RB, Herman DS, Bailey GL, PinkstonCamp MM, Stein MD. Chronic Pain in HIV-Infected Patients: rela
tionship to Depression, Substance Use, and Mental Health and Pain
Treatment. Pain Med. 2015;16(10):1870–1881.
8. Smith MY, Egert J, Winkel G, Jacobson J. The impact of PTSD on
pain experience in persons with HIV/AIDS. Pain. 2002;98(1):9–17.
9. Krashin DL, Merrill JO, Trescot AM. Opioids in the management of
HIV-related pain. Pain Physician. 2012;15(3 Suppl):ES157–ES168.
10. Tsao JC, Stein JA, Dobalian A. Pain, problem drug use history, and
aberrant analgesic use behaviors in persons living with HIV. Pain.
2007;133(1–3):128–137. doi:10.1016/j.pain.2007.03.016
11. Merlin JS, Westfall AO, Raper JL, et al. Pain, mood, and substance
abuse in HIV: implications for clinic visit utilization, antiretroviral
therapy adherence, and virologic failure. J Acquir Immune Defic
Syndr. 2012;61(2):164–170. doi:10.1097/QAI.0b013e3182662215
12. Surratt HL, Kurtz SP, Levi-Minzi MA, Cicero TJ, Tsuyuki K,
O’Grady CL. Pain treatment and antiretroviral medication adherence
among vulnerable HIV-positive patients. AIDS Patient Care STDS.
2015;29(4):186–192. doi:10.1089/apc.2014.0104
13. Berg KM, Cooperman NA, Newville H, Arnsten JH. Self-efficacy
and depression as mediators of the relationship between pain and
antiretroviral adherence. AIDS Care. 2009;21(2):244–248.
doi:10.1080/09540120802001697
14. Papadimitriou
A,
Priftis
KN.
Regulation
of
the
hypothalamic-pituitary-adrenal
axis.
Neuroimmunomodulation.
2009;16(5):265–271. doi:10.1159/000216184
15. McEwen BS. Neurobiological and Systemic Effects of Chronic
Stress. Chronic Stress. 2017;1:1. doi:10.1177/2470547017692328
16. Nicolaides NC, Kyratzi E, Lamprokostopoulou A, Chrousos GP,
Charmandari E. Stress, the stress system and the role of
glucocorticoids.
Neuroimmunomodulation.
2015;22(1–2):6–19.
doi:10.1159/000362736
17. Abdallah CG, Geha P. Chronic pain and chronic stress: two sides of
the same coin? Chronic Stress. 2017;1.

Journal of Pain Research 2021:14

Dovepress
18. Chapman CR, Tuckett RP, Song CW. Pain and stress in a systems
perspective: reciprocal neural, endocrine, and immune interactions.
J Pain. 2008;9(2):122–145. doi:10.1016/j.jpain.2007.09.006
19. Muhtz C, Rodriguez-Raecke R, Hinkelmann K, et al. Cortisol
response to experimental pain in patients with chronic low back
pain and patients with major depression. Pain Med. 2013;14
(4):498–503. doi:10.1111/j.1526-4637.2012.01514.x
20. Petrelluzzi KF, Garcia MC, Petta CA, Grassi-Kassisse DM, SpadariBratfisch RC. Salivary cortisol concentrations, stress and quality of
life in women with endometriosis and chronic pelvic pain. Stress.
2008;11(5):390–397. doi:10.1080/10253890701840610
21. van Aken M, Oosterman J, van Rijn T, et al. Hair cortisol and the
relationship with chronic pain and quality of life in endometriosis
patients. Psychoneuroendocrinology. 2018;89:216–222. doi:10.1016/
j.psyneuen.2018.01.001
22. Turner-Cobb JM, Osborn M, da Silva L, Keogh E, Jessop DS. Sex
differences in hypothalamic-pituitary-adrenal axis function in patients
with chronic pain syndrome. Stress. 2010;13(4):292–300.
doi:10.3109/10253890903524785
23. Vachon-Presseau E, Roy M, Martel MO, et al. The stress model of
chronic pain: evidence from basal cortisol and hippocampal structure
and function in humans. Brain. 2013;136(Pt 3):815–827.
doi:10.1093/brain/aws371
24. Van Uum SH, Sauve B, Fraser LA, Morley-Forster P, Paul TL,
Koren G. Elevated content of cortisol in hair of patients with severe
chronic pain: a novel biomarker for stress. Stress. 2008;11
(6):483–488. doi:10.1080/10253890801887388
25. Perogamvros I, Keevil BG, Ray DW, Trainer PJ. Salivary cortisone is
a potential biomarker for serum free cortisol. J Clin Endocrinol
Metab. 2010;95(11):4951–4958. doi:10.1210/jc.2010-1215
26. Vanaelst B, Michels N, De Vriendt T, et al. Cortisone in hair of
elementary school girls and its relationship with childhood stress. Eur
J Pediatr. 2013;172(6):843–846. doi:10.1007/s00431-013-1955-1
27. Wang W, Deng H, Wang L, Cao C, Xu H, Zhang J. Hair cortisone
level is associated with PTSDs dysphoric arousal symptoms in highly
traumatized Chinese females. J Affect Disord. 2015;182:18–22.
doi:10.1016/j.jad.2015.04.036
28. Zhang Q, Chen Z, Chen S, Xu Y, Deng H. Intraindividual stability of
cortisol and cortisone and the ratio of cortisol to cortisone in saliva, urine
and hair. Steroids. 2017;118:61–67. doi:10.1016/j.steroids.2016.12.008
29. Zhang Q, Chen Z, Chen S, et al. Correlations of hair level with
salivary level in cortisol and cortisone. Life Sci. 2018;193:57–63.
doi:10.1016/j.lfs.2017.11.037
30. Wosu AC, Valdimarsdottir U, Shields AE, Williams DR, Williams MA.
Correlates of cortisol in human hair: implications for epidemiologic stu
dies on health effects of chronic stress. Ann Epidemiol. 2013;23(12):797–
811 e792. doi:10.1016/j.annepidem.2013.09.006
31. Stalder T, Kirschbaum C. Analysis of cortisol in hair–state of the art
and future directions. Brain Behav Immun. 2012;26(7):1019–1029.
doi:10.1016/j.bbi.2012.02.002
32. Short SJ, Stalder T, Marceau K, et al. Correspondence between hair
cortisol concentrations and 30-day integrated daily salivary and
weekly urinary cortisol measures. Psychoneuroendocrinology.
2016;71:12–18. doi:10.1016/j.psyneuen.2016.05.007
33. Sugaya N, Izawa S, Ogawa N, Shirotsuki K, Nomura S. Association
between hair cortisol and diurnal basal cortisol levels: a 30-day
validation study. Psychoneuroendocrinology. 2020;116:104650.
doi:10.1016/j.psyneuen.2020.104650
34. Chen Z, Zhang Q, Chen S, Wang W, Liu G, Deng H. Determination,
intercorrelation and intraindividual stability of five steroids in hair,
saliva and urine among chinese college students. Steroids.
2019;149:108418. doi:10.1016/j.steroids.2019.05.010
35. Stalder T, Steudte S, Miller R, Skoluda N, Dettenborn L,
Kirschbaum C. Intraindividual stability of hair cortisol
concentrations. Psychoneuroendocrinology. 2012;37(5):602–610.
doi:10.1016/j.psyneuen.2011.08.007

Journal of Pain Research 2021:14

Zhang et al
36. Davison B, Singh GR, McFarlane J. Hair cortisol and cortisone as
markers of stress in Indigenous and non-Indigenous young adults.
Stress. 2019;22:1–11.
37. Feeney JC, O’Halloran AM, Kenny RA. The association between
hair cortisol, hair cortisone, and cognitive function in a
population-based cohort of older adults: results from the irish long
itudinal study on ageing. J Gerontology. 2018.
38. Musana JW, Cohen CR, Kuppermann M, et al. Association of differ
ential symptoms of stress to hair cortisol and cortisone concentrations
among pregnant women in Kenya. Stress. 2019;23:1–11.
39. Scharlau F, Pietzner D, Vogel M, et al. Evaluation of hair cortisol and
cortisone change during pregnancy and the association with
self-reported depression, somatization, and stress symptoms. Stress.
2018;21(1):43–50.
40. van den Heuvel LL. du Plessis S, Stalder T, et al. Hair glucocorticoid levels
in Parkinson’s disease. Psychoneuroendocrinology. 2020;117:104704.
41. Qiao S, Li X, Zilioli S, et al. Hair measurements of cortisol, DHEA,
and DHEA to cortisol ratio as biomarkers of chronic stress among
people living with HIV in china: known-group validation. PLoS One.
2017;12(1):e0169827.
42. Langerak T, van den Dries LW, Wester VL, et al. The relation
between long-term cortisol levels and the metabolic syndrome in
HIV-infected patients. Clin Endocrinol (Oxf). 2015;83(2):167–172.
43. Yang X, Li X, Qiao S, Zhang Q, Shen Z, Zhou Y. Immunological and
virologic outcomes of people living with HIV in Guangxi, China:
2012–2017. PLoS One. 2019;14(3):e0213205.
44. Zhang Q, Li X, Qiao S, Shen Z, Zhou Y. Comparing self-reported
medication adherence measures with hair antiretroviral concentration
among people living with HIV in Guangxi, China. AIDS Res Ther.
2020;17(1):8.
45. Zhang Q, Li X, Qiao S, Shen Z, Zhou Y. Factors influencing hair
lamivudine concentration among people living with HIV in Guangxi,
China. Antivir Ther. 2020;25(3):143–149.
46. Cooper GA, Kronstrand R, Kintz P. Society of Hair T. society of hair
testing guidelines for drug testing in hair. Forensic Sci Int. 2012;218
(1–3):20–24.
47. Sachs H. Quality control by the Society of Hair Testing. Forensic Sci
Int. 1997;84(1–3):145–150.
48. Lau JT, Tsui HY, Patrick LC, Rita CW, Molassiotis A. Validation of
a Chinese version of the Medical Outcomes Study HIV Health
Survey (MOS-HIV) among Chinese people living with HIV/AIDS
in Hong Kong. Qual Life Res. 2006;15(6):1079–1089.
49. Wu AW, Revicki DA, Jacobson D, Malitz FE. Evidence for
reliability, validity and usefulness of the Medical Outcomes
Study HIV Health Survey (MOS-HIV). Qual Life Res. 1997;6
(6):481–493.
50. Gao W, Stalder T, Foley P, Rauh M, Deng H, Kirschbaum C.
Quantitative analysis of steroid hormones in human hair using a
column-switching LC-APCI-MS/MS assay. J Chromatogr B Analyt
Technol Biomed Life Sci. 2013;928:1–8.
51. Rippe RC, Noppe G, Windhorst DA, et al. Splitting hair for cortisol?
Associations of socio-economic status, ethnicity, hair color, gender
and other child characteristics with hair cortisol and cortisone.
Psychoneuroendocrinology. 2016;66:56–64.
52. Staufenbiel SM, Penninx BW, de Rijke YB, van den Akker EL, van
Rossum EF. Determinants of hair cortisol and hair cortisone concen
trations in adults. Psychoneuroendocrinology. 2015;60:182–194.
53. Dixon WJ, Yuen KK. Trimming and winsorization: a review.
Statistische Hefte. 1974;15(2–3):157–170.
54. Clark JE, Osborne JW, Gallagher P, Watson S. A simple method for
optimising transformation of non-parametric data: an illustration by refer
ence to cortisol assays. Hum Psychopharmacol. 2016;31(4):259–267.
55. Kuehl LK, Hinkelmann K, Muhtz C, et al. Hair cortisol and cortisol
awakening response are associated with criteria of the metabolic
syndrome in opposite directions. Psychoneuroendocrinology.
2015;51:365–370.

submit your manuscript | www.dovepress.com

DovePress

Powered by TCPDF (www.tcpdf.org)

651

Zhang et al
56. Stalder T, Kirschbaum C, Alexander N, et al. Cortisol in hair and the
metabolic syndrome. J Clin Endocrinol Metab. 2013;98
(6):2573–2580.
57. Savas M, Wester VL, de Rijke YB, et al. Hair glucocorticoids as
a biomarker for endogenous cushing’s syndrome: validation in two
independent cohorts. Neuroendocrinology. 2019;109(2):171–178.
58. Hilton L, Hempel S, Ewing BA, et al. Mindfulness meditation for
chronic pain: systematic review and meta-analysis. Ann Behav Med.
2017;51(2):199–213.

Journal of Pain Research

Dovepress
59. Goldberg SB, Manley AR, Smith SS, et al. Hair cortisol as
a biomarker of stress in mindfulness training for smokers. J Altern
Complement Med. 2014;20(8):630–634.
60. Gray NA, Dhana A, Van Der Vyver L, Van Wyk J, Khumalo NP,
Stein DJ. Determinants of hair cortisol concentration in children:
a systematic review. Psychoneuroendocrinology. 2018;87:204–214.

Dovepress

Publish your work in this journal
The Journal of Pain Research is an international, peer reviewed, open
access, online journal that welcomes laboratory and clinical findings in
the fields of pain research and the prevention and management of pain.
Original research, reviews, symposium reports, hypothesis formation
and commentaries are all considered for publication. The manuscript

management system is completely online and includes a very quick
and fair peer-review system, which is all easy to use. Visit http://
www.dovepress.com/testimonials.php to read real quotes from pub
lished authors.

Submit your manuscript here: https://www.dovepress.com/journal-of-pain-research-journal

652

Powered by TCPDF (www.tcpdf.org)

submit your manuscript | www.dovepress.com

DovePress

Journal of Pain Research 2021:14

